2
Key Points
➤ An increasing number of therapies are approved to treat cancers
harboring specific genomic biomarkers.
➤ All cancers with regulatory-approved biomarkers that guide therapy
choice should undergo genomic sequencing.
➤ Multi-gene panel testing should be conducted whenever more than
one genomic biomarker is linked to a regulatory agency-approved
therapy in the patient's disease.
➤ Multi-gene panel testing is also beneficial when considering
immunotherapies with genomic biomarker-linked site-agnostic
approvals and to identify additional targets when there are few or no
genotype-based therapy approvals for the patient's disease.
➤ Clinicians should consider the functional impact of the targeted
alteration and the expected efficacy of genomic biomarker-linked-
options relative to other treatments during treatment planning.
➤ Clinical trials are encouraged.
➤ Genomic sequencing should be performed within a certified
laboratory.